Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) Equity Average (2018 - 2021)

Cogent Biosciences has reported Equity Average over the past 4 years, most recently at $205.0 million for Q3 2021.

  • Quarterly results put Equity Average at $205.0 million for Q3 2021, up 14080.29% from a year ago — trailing twelve months through Sep 2021 was $205.0 million (up 14080.29% YoY), and the annual figure for FY2020 was $133.2 million, up 189.61%.
  • Equity Average for Q3 2021 was $205.0 million at Cogent Biosciences, down from $219.8 million in the prior quarter.
  • Over the last five years, Equity Average for COGT hit a ceiling of $230.7 million in Q1 2021 and a floor of -$55.1 million in Q1 2018.
  • Median Equity Average over the past 4 years was $44.5 million (2019), compared with a mean of $70.9 million.
  • Biggest five-year swings in Equity Average: tumbled 104.29% in 2020 and later soared 14080.29% in 2021.
  • Cogent Biosciences' Equity Average stood at $63.9 million in 2018, then plummeted by 52.74% to $30.2 million in 2019, then skyrocketed by 251.9% to $106.2 million in 2020, then soared by 92.97% to $205.0 million in 2021.
  • The last three reported values for Equity Average were $205.0 million (Q3 2021), $219.8 million (Q2 2021), and $230.7 million (Q1 2021) per Business Quant data.